title: [Treatment-resistant anxiety disorders: A literature review of drug therapy strategies].
abstract: Anxiety disorders are widespread psychiatric conditions with significant social and professional disability, poor quality of life, an increased risk of suicide, and frequent attendance of medical services. Serotonin reuptake inhibitors (SRI) and serotonin and norepinephrine reuptake inhibitors (SNRI) have demonstrated a rather robust efficacy for the treatment of most of anxiety disorders. Nevertheless a substantial number of patients are resistant or still suffer from residual symptoms despite this first line treatment. The objective of our paper is to review relevant studies for the pharmacologic management of anxiety disorders resistant to the first line treatment. For this purpose, we conducted a pubmed/medline search for double-blind placebo-controlled trials of treatment-resistant anxiety disorders. An adequate trial for a SRI in the treatment of obsessive-compulsive disorder (OCD) should continue for at least 12 weeks. Special considerations of the comorbidities and symptom profile could help in the choice of an appropriate pharmacotherapy. Several trials have highlighted the efficacy of antipsychotics as an add-on to SRI in treatment-resistant OCD such as haloperidol more so when comorbid with a tic disorder, or risperidone that can reduce OCD as well as depressive symptoms. Aripiprazole has been shown efficacious in two placebo-controlled double-blind trials, while the efficacy of quetiapine and olanzapine remains controversial. Other trials showed some efficacy of anticonvulsants (lamotrigine, topiramate), pindolol, memantin and N-acetylcystein as an adjunctive treatment to SRI for resistant OCD. Few trials have investigated selective serotonin reuptake inhibitors (SSRI) or SNRI resistant generalized anxiety disorder showing a failure of adjunctive therapy with olanzapine, quetiapine, ziprasidone and risperidone. These studies were underpowered and very limited in number. Adjunctive risperidone for resistant post-traumatic stress disorder (PTSD) showed benefit in some but not all trials. Olanzapine was beneficial for the reduction of the CAPS score in addition to the improvement of sleep disturbances. Furthermore, prazosin was efficacious by reducing PTSD symptoms, sleep disturbances, nightmares, and psychological distress. One double-blind placebo-controlled study was conducted to investigate treatment-resistant social phobia showing no benefit of pindolol add-on paroxetine. Our results demonstrate that the pharmacological management of treatment-resistant anxiety disorders is not sufficiently investigated in double-blind placebo-controlled trials, despite a growing evidence in favor of antipsychotics and some other pharmacological agents in resistant OCD and, to a lesser extent, PTSD. Hence, there is a crucial need for larger double-blind placebo-controlled trials for resistant anxiety disorders. Finally, being out of the scope of our review, we omitted studies of non-pharmacologic therapies.
authors.affiliation: Service de psychiatrie, faculté des sciences médicales, université Libanaise, Beyrouth, Liban.
authors.forename: G
authors.initials: G
authors.lastname: Ammar
authors.affiliation: Service de psychiatrie, faculté des sciences médicales, université Libanaise, Beyrouth, Liban.
authors.forename: W J
authors.initials: WJ
authors.lastname: Naja
authors.affiliation: Service de psychiatrie, hôpital Henri-Mondor, AP-HP, université Paris-Est Créteil, Inserm U955, Fondation FondaMental, 51, avenue du Maréchal-de-Latttre-de-Tassigny, 94000 Créteil, France. Electronic address: antoine.pelissolo@inserm.fr.
authors.forename: A
authors.initials: A
authors.lastname: Pelissolo
mesh_terms: D014151:Anti-Anxiety Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001008:Anxiety Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D018849:Controlled Clinical Trials as Topic; D004311:Double-Blind Method; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D006801:Humans; D008134:Long-Term Care; D009638:Norepinephrine / Q000037:antagonists & inhibitors*; D009771:Obsessive-Compulsive Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D010698:Phobic Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000523:psychology; D012008:Recurrence; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D013313:Stress Disorders, Post-Traumatic / Q000175:diagnosis / Q000188:drug therapy / Q000523:psychology
chemical_list: D014151:Anti-Anxiety Agents; D000927:Anticonvulsants; D014150:Antipsychotic Agents; D009638:Norepinephrine; D017367:Selective Serotonin Reuptake Inhibitors
keywords: Antidepressants; Antidépresseurs; Anxiety disorders; Obsessive-compulsive disorder; Pharmacotherapy; Pharmacothérapies; Refractory patients; Résistance; Troubles anxieux; Troubles obsessionnels-compulsifs